Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicenter, Randomized Controlled Clinical Study of Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

NCT05253066 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT05253066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicenter, Randomized Controlled Clinical Study of Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Lead sponsor
Shengjing Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
February 25, 2022
Completion date
January 31, 2025
Enrollment
130 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms